Themis Bioscience

Prophylactic vaccines for infectious diseases

placeVienna, Vienna, Austria calendar_todayFounded 2009 groups40 employees language themisbio.com

Innovation

5 patent families (2 granted) — focus: Human necessities, Chemistry & metallurgy; filing pace slowing. Cited 518 times.

YearFilings
20141
20151
20161
20172
20182
20193
20202
20213
20223
20232

Investor mix

16 investors on record; lead investors include Global Health Investment Fund, Omnes Capital, Ventech, Wellington Partners Venture Capital; 2 have since exited.

Investor typeCountShare
Venture capital638%
Private equity319%
Accelerator & incubator16%
Bank & private debt16%
Other / undisclosed531%
Coming soon